WASHINGTON (AP) -- Doctors and parents should watch for signs of bizarre behavior such as delirium and hallucinations in children treated with the flu drug Tamiflu, federal health officials suggested Monday, citing increasing cases overseas.
Food and Drug Administration officials still don't know if the more than 100 new cases, including three deaths from falls, are linked to the drug or to the flu virus - or a combination of both. Most of the reported cases involved children.
Still, FDA staff suggested updating Tamiflu's label to recommend that all patients, especially children, be closely monitored while on the drug.
They also acknowledged that stopping treatment with Tamiflu could actually harm influenza patients if the virus is the cause of delirium, hallucinations and other abnormal behavior, such as aggression and suicidal thoughts.
The FDA's pediatric advisory committee is to discuss the recommendation Thursday. The FDA isn't required to follow the advice of its outside panels but usually does. An FDA spokeswoman did not immediately return a call seeking comment.
The meeting comes a year after the same panel of outside experts rejected linking Tamiflu to reports of 12 deaths in Japanese children since 2000 and voted against changing the drug's label to suggest any such concern. At that time, however, the committee did recommend that the FDA continue to monitor the drug's safety and return a year later with an update.
The panel's decision after reviewing the new update is likely to be closely watched, since Tamiflu could play an important role in an outbreak of bird flu. The drug doesn't prevent flu but can reduce the length and severity of its symptoms.
Most of the 103 new cases of bizarre behavior are from Japan, where Tamiflu usage is the highest in the world. Between 2001 and 2005, Tamiflu was prescribed 24.5 million times in Japan, compared with just 6.5 million in the United States, which has more than twice the population, according to FDA.
The new cases occurred during a 10-month period, between Aug. 29, 2005, and July 6, 2006. The tally marks a sharp increase to the 126 similar cases logged over the more than five years between the drug's approval in 1999 and August 2005, the FDA said.
The Japanese Tamiflu label now warns that disturbances in consciousness, abnormal behavior, delirium, hallucination, delusion and convulsion may occur. It also recommends that patients be carefully monitored and the drug stopped if any abnormality is observed.
Even though severe cases of the flu can spark those conditions, the number and nature of the cases - along with comments from doctors who believe the abnormal behavior was associated with the drug - keep the FDA from ruling out Tamiflu as the cause, according to agency documents.
For that reason, the proposed changes would bring the U.S. label more in line with the Japanese one, and warn of abnormal behavior and recommend that patients, especially children, be closely monitored.
However, the proposed U.S. version would recommend treatment be stopped only on a doctor's advice.
FDA staff called the proposed changes "prudent," since U.S. Tamiflu use could jump to Japanese levels. The current U.S. label mentions only "seizure and confusion" seen in some patients.
Tamiflu is made by the Swiss pharmaceutical company Roche Holding AG. Roche has been in ongoing discussions with FDA about a label change, and continues to monitor the safety of Tamiflu, also known as oseltamivir, said company spokesman Terence Hurley. He added there was no evidence the drug caused the rarely occurring adverse events.
Previously, Roche has cited studies from the United States and Canada that show the death incidence rate of influenza patients who took Tamiflu was far below those who did not.
Tamiflu is one of the few drugs believed effective in treating bird flu, which health officials fear could spark a pandemic should it mutate into a form easily passed from human to human.
According to the label, Tamiflu is indicated for the treatment of uncomplicated acute illness due to flu in patients 1 year and older who have been symptomatic for no more than 2 days.